M&T Bank’s Vaxcyte PCVX Stock Holding History

M&T Bank’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$248K	Buy	4,275 +35	+0.8%	+$1.9K	﹤0.01%	1553
2026 Q1	$246K	Buy	+4,240	New	+$230K	﹤0.01%	1476

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

M&T Bank's PCVX Position: Q2 2026 in Review

M&T Bank increased its Vaxcyte (PCVX) stake by 0.83% in Q2 2026, buying an estimated $1.9K and bringing the position to 4,275 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #1553.

M&T Bank first reported a position in PCVX in Q1 2026 and has held it in 2 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

M&T Bank held 4,275 shares of Vaxcyte worth $248K as of Q2 2026.
M&T Bank bought 35 Vaxcyte shares in Q2 2026, an estimated $1.9K.
Vaxcyte made up ﹤0.01% of M&T Bank's portfolio in Q2 2026, its #1553 holding.
M&T Bank first reported a position in Vaxcyte in Q1 2026 and has held it in 2 quarters since.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.